{
    "2021-03-18": [
        [
            {
                "time": "",
                "original_text": "医药界的“小恒瑞”！创新药隐形冠军，毛利率比茅台、恒瑞还高",
                "features": {
                    "keywords": [
                        "医药",
                        "创新药",
                        "毛利率",
                        "恒瑞",
                        "茅台"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "创纪录！人民金融·创新药指数涨2.88%！16个品种获批临床，贝达药业进军双抗，多款创新药取得重大进展",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "涨2.88%",
                        "贝达药业",
                        "双抗",
                        "临床",
                        "重大进展"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "创新药板块热度不减，双鹭、海思科、丽珠、人福、贝达、康龙化成均大涨",
                "features": {
                    "keywords": [
                        "创新药",
                        "双鹭",
                        "海思科",
                        "丽珠",
                        "人福",
                        "贝达",
                        "康龙化成",
                        "大涨"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国金证券上调贝达药业评级至买入：多款产品即将上市，自主研发逐步验证，目标价145元",
                "features": {
                    "keywords": [
                        "国金证券",
                        "贝达药业",
                        "买入",
                        "产品上市",
                        "自主研发",
                        "目标价145元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}